Evidence-based articles on GLP-1 side effects, pricing, generics and safety.
Generic semaglutide is now launching in India, Canada, and Brazil. Is it the same as Ozempic? Here's what equivalence actually means — and what to look for.
Read moreOzempic costs €300+ per month in some countries and €14 in others. Here's the patent economics behind the price — and why 2026 is changing everything.
Read moreConsidering semaglutide for weight management? Here's what to expect in week 1, month 1, and beyond — from dose titration to side effects to lifestyle pairings.
Read moreCounterfeit and grey market semaglutide is a growing problem. Here's how to tell if what you're buying is the real thing — and what to do if you're not sure.
Read moreIndia's semaglutide patent expired March 20, 2026. Within 48 hours, 15 generic versions launched at ₹1,290/month — a 90% drop from Ozempic. Here's what it means for Indian patients.
Read moreA clear, non-hype explanation of what semaglutide actually does inside your body — the gut, the brain, the pancreas — and why that matters for how you take it.
Read moreThree brand names, two molecules, very different labels. Here's an honest comparison of Ozempic, Wegovy, and Mounjaro — what the differences actually mean for patients.
Read moreNausea is the most common reason people stop semaglutide in the first month. Here's a practical, evidence-based playbook for getting through the first four weeks.
Read moreGLP-1 drugs like semaglutide and tirzepatide are not for everyone. Here's an honest list of who should not take them, and why — from contraindications to caution cases.
Read moreGLP-1 drugs do a lot, but diet still matters — maybe more than you think. Here's what to eat to protect muscle, avoid nausea, and get the most out of semaglutide.
Read moreRetatrutide, an experimental triple-agonist weight loss drug, has been linked to emotional blunting and reduced romantic feelings. What does the science say?
Read moreFrom GLP-1 to dual and triple agonists: how do these molecules work in your body? The chemistry behind weight management, explained without jargon.
Read moreAn honest overview of the side effects, risks and safety data of weight management medication. What does the science say? And how do you minimise risks?
Read moreYou visit your dietitian but the weight won't budge. When is it time for medical support alongside nutritional advice? And what does it cost in 2026?
Read moreTried Weight Watchers, Noom or another diet programme without results? Discover why dieting alone often isn't enough and what medical alternatives are available.
Read moreBranded medications for weight loss cost €150-500/month and are mostly not reimbursed in 2026. Discover the alternative via compounding, priced independently with your pharmacy.
Read moreMedical weight loss doesn't have to be expensive. Compare the costs of every option in the Netherlands: from dietitians to compounding pharmacies. Discover the affordable alternative.
Read moreCompounding is the custom preparation of medication by a pharmacist. Discover how it works, why it's legal, and what the advantages are compared to standard branded products.
Read moreDiscover why more and more Dutch people are choosing personalised weight management programmes via compounding pharmacies. Affordable, effective and under medical supervision.
Read moreCompare compounded preparations with standard branded products. Costs, quality, dosage and safety — everything laid out for Dutch consumers.
Read moreThis article described a 4-step Magistra service — questionnaire, doctor assessment, pharmacy matching and delivery. That service does not exist. What a compounded treatment in the Netherlands generally requires, and what Magistra does publish: independent GLP-1 data.
Read moreHow safe are compounded preparations? An overview of Dutch and European regulation, quality controls and registration requirements for compounding pharmacies.
Read moreAn honest comparison of the costs of weight management programmes in the Netherlands. From dietitians to branded products to compounding — what does it really cost?
Read moreHow do you find a licensed compounding pharmacy in the Netherlands yourself, and what should you look for — BIG registration, IGJ inspection, facilities? Magistra does not operate a pharmacy finder; we publish independent GLP-1 data.
Read moreCalculate your BMI and discover when a personalised weight management programme makes sense. With an explanation of BMI categories and your options in the Netherlands.
Read moreMagistra stores no personal health record. What we do keep (waitlist email, contact message), where it lives (EU), and what GDPR rights you have.
Read moreDiet pills vs. compounding: what's the difference? Why personalised programmes via a doctor and pharmacy are safer and more effective.
Read moreAn evidence-grounded look at the Chinese semaglutide and tirzepatide peptide trade — what an independent lab test can and cannot tell you about a vial, the legal reality country by country, and what patients should know before relying on this supply chain.
Read moreAn evidence-grounded forecast of GLP-1 medication supply and demand through 2030. Manufacturing capacity, generic ramp, demand drivers (cardiovascular, kidney, sleep apnea, oral formulations), the role of insurance unlock, and what the 2031 OECD generic wave actually means for affordability.
Read moreWhat happens when one country has $40/month generic semaglutide and another has $1,349/month branded — until 2031? An evidence-grounded look at the legal arbitrage now opening up: who travels to India, what gets through customs, the difference between the Indian-generic gray market and the Chinese-peptide gray market, and how the trade likely evolves.
Read moreIn January 2026 the GPhC tightened the rules on how UK pharmacies can supply Wegovy, Mounjaro and other weight-loss jabs. Online questionnaire-only prescribing is no longer permitted; pharmacies must conduct a two-way consultation and independently verify BMI. Here's what changed, why, and what it means for patients seeking treatment and doctors providing it.
Read moreWe audited every UK company with 'peptide' in its name on Companies House. 98 are brand new with no track record, none of the credible ones supply GLP-1, and one woman has already died. Here's what patients need to know — and the safe alternative.
Read moreWe track 15 GLP-1 side effects in our real-world evidence database. After a 31 August 2026 correction excluded seed rows from the eligible base, only 1 currently clears our bar for a fully calibrated statistical model. Here's exactly which one, why, and what's published instead for the other 14.
Read more14 of the 15 GLP-1 side effects we track have a published rate pooled directly from our own corpus of clinical trial and regulatory sources — not copied from a single paper. Here is every number, with its confidence interval, exactly how many sources it rests on, and the corrections that shaped the eligible base.
Read moreOf the distinct community reports we hold from people on GLP-1 medications — Reddit threads and Drugs.com patient reviews — which side effects come up most? All 15 reporting frequencies with their denominator, what this number deliberately is not (an incidence rate), why we count mentions instead of averaging what posts claim, and the 2026-08-29 correction that cut the pool from 185 reports to 26.
Read moreThe US label warns that gallstone risk goes up. A meta-analysis of 76 randomized trials agrees — especially at weight-loss doses. A 32,052-patient cohort study published in December 2025 found the opposite direction in one high-risk population. Here is every number, the population it belongs to, and what our own evidence base holds.
Read morePersonalised risk tools give you one number. It is really two ingredients multiplied together — an evidenced base rate and a set of profile multipliers — and almost nobody shows you the second. Here are all 75 of ours, including the fact that none of them carries a citation.
Read moreThe US semaglutide label puts hair loss at 3% versus 1% on placebo, and says it was associated with weight reduction and reported several times more often in women than in men. The tirzepatide registry posts alopecia per arm at about 5% versus 1.1%, and as of 7 September 2026 those three arms are also our own database's first eligible clinical rates for the effect — here is every number, the arm and n it belongs to.
Read moreSearch "how common is vomiting on Ozempic" and every answer gives you one number with no source. Our own corpus held 15 distinct sources that state a vomiting rate on 10 September 2026 — fourteen trials and one review quoting a fifteenth — and they range from 6.5% (an 8,803-patient cardiovascular outcome trial) to 58% (a 6-person early-phase pharmacology study). Both are real. Here is every trial, its population, its n, and why the range is this wide rather than a defect in the data.
Read moreThe US semaglutide label puts constipation at 24% on Wegovy 2.4 mg against 11% on placebo, so nearly half the headline is the background rate. We read the placebo arm of every constipation source in our corpus that posts one — from an 8,803-patient cardiovascular trial to a 61-participant dose-ranging study — and in the weight-reduction trials the label itself pools, the drug-minus-placebo difference is 11 to 14 points every time. Here is every arm, its n, and why our own pooled 11.8% is not the Wegovy number.
Read moreSee your personal GLP-1 side-effect risk